These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6768943)

  • 1. L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression.
    Mann J; Gershon S
    Life Sci; 1980 Mar; 26(11):877-82. PubMed ID: 6768943
    [No Abstract]   [Full Text] [Related]  

  • 2. The relative efficacy of l-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression.
    Mann JJ; Frances A; Kaplan RD; Kocsis J; Peselow ED; Gershon S
    J Clin Psychopharmacol; 1982 Feb; 2(1):54-7. PubMed ID: 6802883
    [No Abstract]   [Full Text] [Related]  

  • 3. Platelet monoamine oxidase inhibition by deprenyl and tranylcypromine: implications for clinical use.
    Simpson GM; Frederickson E; Palmer R; Pi E; Sloane RB; White K
    Biol Psychiatry; 1985 Jun; 20(6):684-7. PubMed ID: 3922441
    [No Abstract]   [Full Text] [Related]  

  • 4. L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation.
    Mendlewicz J; Youdim MB
    Br J Psychiatry; 1983 May; 142():508-11. PubMed ID: 6409196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy.
    Lee DH; Mendoza M; Dvorozniak MT; Chung E; van Woert MH; Yahr MD
    J Neural Transm Park Dis Dement Sect; 1989; 1(3):189-94. PubMed ID: 2505797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
    Sandler M
    J Neural Transm Suppl; 1986; 22():107-15. PubMed ID: 3097254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An early phase II trial with L-deprenyl for the treatment of neuroleptic-induced parkinsonism.
    Perényi A; Bagdy G; Arató M
    Pharmacopsychiatria; 1983 Sep; 16(5):143-6. PubMed ID: 6140692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical effects of L-deprenyl in atypical depressives.
    Liebowitz MR; Karoum F; Quitkin FM; Davies SO; Schwartz D; Levitt M; Linnoila M
    Biol Psychiatry; 1985 May; 20(5):558-65. PubMed ID: 3921065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of L-Deprenyl on on-off phenomena in Parkinson's disease.
    Brodersen P; Philbert A; Gulliksen G; Stigård A
    Acta Neurol Scand; 1985 Jun; 71(6):494-7. PubMed ID: 3927650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
    Riederer P; Youdim MB
    J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose regimen of deprenyl (selegiline) and platelet MAO activities.
    Oreland L; Johansson F; Ekstedt J
    Acta Neurol Scand Suppl; 1983; 95():87-9. PubMed ID: 6428150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO "type B" inhibitor.
    Mendlewicz J; Youdim MB
    J Neural Transm; 1978; 43(3-4):279-86. PubMed ID: 745020
    [No Abstract]   [Full Text] [Related]  

  • 13. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
    Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A
    N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
    Tetrud JW; Langston JW
    Science; 1989 Aug; 245(4917):519-22. PubMed ID: 2502843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report.
    Higuchi H; Kamata M; Sugawara Y; Yoshida K
    Clin Neuropharmacol; 2005; 28(4):191-2. PubMed ID: 16062100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
    Amato L; Nava L; Rizzo M; Piccoli F
    Riv Neurol; 1985; 55(1):46-52. PubMed ID: 3927468
    [No Abstract]   [Full Text] [Related]  

  • 17. l-Deprenyl in atypical depressives.
    Quitkin FM; Liebowitz MR; Stewart JW; McGrath PJ; Harrison W; Rabkin JG; Markowitz J; Davies SO
    Arch Gen Psychiatry; 1984 Aug; 41(8):777-81. PubMed ID: 6430257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the mode of action of L-deprenyl in the human central nervous system.
    Riederer P; Youdim MB; Rausch WD; Birkmayer W; Jellinger K; Seemann D
    J Neural Transm; 1978; 43(3-4):217-26. PubMed ID: 745014
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential efficacy of L-deprenyl, a selective MAO type-B inhibitor, in endogenous and nonendogenous depression.
    Mann JJ; Frances A; Peselow ED; Gershon S
    Psychopharmacol Bull; 1982 Oct; 18(4):182-4. PubMed ID: 6818606
    [No Abstract]   [Full Text] [Related]  

  • 20. Deprenyl in Parkinson disease.
    Eisler T; Teräväinen H; Nelson R; Krebs H; Weise V; Lake CR; Ebert MH; Whetzel N; Murphy DL; Kopin IJ; Calne DB
    Neurology; 1981 Jan; 31(1):19-23. PubMed ID: 6161320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.